334 related articles for article (PubMed ID: 28526744)
1. Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity.
Gong GQ; Kendall JD; Dickson JMJ; Rewcastle GW; Buchanan CM; Denny WA; Shepherd PR; Flanagan JU
Biochem J; 2017 Jun; 474(13):2261-2276. PubMed ID: 28526744
[TBL] [Abstract][Full Text] [Related]
2. Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases.
Sabbah DA; Vennerstrom JL; Zhong H
J Chem Inf Model; 2010 Oct; 50(10):1887-98. PubMed ID: 20866085
[TBL] [Abstract][Full Text] [Related]
3. Ligand-Based Drug Design: Synthesis and Biological Evaluation of Substituted Benzoin Derivatives as Potential Antitumor Agents.
Sabbah DA; Ibrahim AH; Talib WH; Alqaisi KM; Sweidan K; Bardaweel SK; Sheikha GA; Zhong HA; Al-Shalabi E; Khalaf RA; Mubarak MS
Med Chem; 2019; 15(4):417-429. PubMed ID: 30207238
[TBL] [Abstract][Full Text] [Related]
4. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
[TBL] [Abstract][Full Text] [Related]
5. Discovery and synthesis of a novel series of potent, selective inhibitors of the PI3Kα: 2-alkyl-chromeno[4,3-c]pyrazol-4(2H)-one derivatives.
Yin Y; Wu X; Han HW; Sha S; Wang SF; Qiao F; Lu AM; Lv PC; Zhu HL
Org Biomol Chem; 2014 Dec; 12(45):9157-65. PubMed ID: 25296388
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis and Biological Evaluation of Novel Benzothiazole Derivatives as Selective PI3Kβ Inhibitors.
Cao S; Cao R; Liu X; Luo X; Zhong W
Molecules; 2016 Jul; 21(7):. PubMed ID: 27384552
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel 2-piperidinol-3-(arylsulfonyl)quinoxalines as phosphoinositide 3-kinase α (PI3Kα) inhibitors.
Wu P; Su Y; Liu X; Yang B; He Q; Hu Y
Bioorg Med Chem; 2012 May; 20(9):2837-44. PubMed ID: 22480851
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel condensed pyrrolo[1,2-c]pyrimidines featuring morpholine moiety as PI3Kα inhibitors.
Ibrahim MA; Abou-Seri SM; Hanna MM; Abdalla MM; El Sayed NA
Eur J Med Chem; 2015 Jun; 99():1-13. PubMed ID: 26037808
[TBL] [Abstract][Full Text] [Related]
9. Benzoin Schiff Bases: Design, Synthesis, and Biological Evaluation as Potential Antitumor Agents.
Sabbah DA; Al-Tarawneh F; Talib WH; Sweidan K; Bardaweel SK; Al-Shalabi E; Zhong HA; Abu Sheikha G; Abu Khalaf R; Mubarak MS
Med Chem; 2018; 14(7):695-708. PubMed ID: 29651943
[TBL] [Abstract][Full Text] [Related]
10. Class I phospho-inositide-3-kinases (PI3Ks) isoform-specific inhibition study by the combination of docking and molecular dynamics simulation.
Han M; Zhang JZ
J Chem Inf Model; 2010 Jan; 50(1):136-45. PubMed ID: 19928754
[TBL] [Abstract][Full Text] [Related]
11. The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
Heffron TP; Heald RA; Ndubaku C; Wei B; Augistin M; Do S; Edgar K; Eigenbrot C; Friedman L; Gancia E; Jackson PS; Jones G; Kolesnikov A; Lee LB; Lesnick JD; Lewis C; McLean N; Mörtl M; Nonomiya J; Pang J; Price S; Prior WW; Salphati L; Sideris S; Staben ST; Steinbacher S; Tsui V; Wallin J; Sampath D; Olivero AG
J Med Chem; 2016 Feb; 59(3):985-1002. PubMed ID: 26741947
[TBL] [Abstract][Full Text] [Related]
12. Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.
Poulsen A; Nagaraj H; Lee A; Blanchard S; Soh CK; Chen D; Wang H; Hart S; Goh KC; Dymock B; Williams M
J Chem Inf Model; 2014 Nov; 54(11):3238-50. PubMed ID: 25317974
[TBL] [Abstract][Full Text] [Related]
13. Structure-Based Design: Synthesis, X-ray Crystallography, and Biological Evaluation of N-Substituted-4-Hydroxy-2-Quinolone-3-Carboxamides as Potential Cytotoxic Agents.
Sabbah DA; Hishmah B; Sweidan K; Bardaweel S; AlDamen M; Zhong HA; Abu Khalaf R; Hasan Ibrahim A; Al-Qirim T; Abu Sheikha G; Mubarak MS
Anticancer Agents Med Chem; 2018; 18(2):263-276. PubMed ID: 28901259
[TBL] [Abstract][Full Text] [Related]
14. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J
Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582
[TBL] [Abstract][Full Text] [Related]
15. Binding selectivity studies of phosphoinositide 3-kinases using free energy calculations.
Sabbah DA; Vennerstrom JL; Zhong HA
J Chem Inf Model; 2012 Dec; 52(12):3213-24. PubMed ID: 23157418
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα inhibitors.
Zhu W; Chen C; Sun C; Xu S; Wu C; Lei F; Xia H; Tu Q; Zheng P
Eur J Med Chem; 2015 Mar; 93():64-73. PubMed ID: 25659752
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
Zhang N; Yu Z; Yang X; Zhou Y; Wang J; Zhang SL; Wang MW; He Y
Eur J Med Chem; 2018 Oct; 158():707-719. PubMed ID: 30245395
[TBL] [Abstract][Full Text] [Related]
18. Exploring a non-ATP pocket for potential allosteric modulation of PI3Kα.
Gkeka P; Papafotika A; Christoforidis S; Cournia Z
J Phys Chem B; 2015 Jan; 119(3):1002-16. PubMed ID: 25299356
[TBL] [Abstract][Full Text] [Related]
19. Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform.
Heffron TP; Wei B; Olivero A; Staben ST; Tsui V; Do S; Dotson J; Folkes AJ; Goldsmith P; Goldsmith R; Gunzner J; Lesnick J; Lewis C; Mathieu S; Nonomiya J; Shuttleworth S; Sutherlin DP; Wan NC; Wang S; Wiesmann C; Zhu BY
J Med Chem; 2011 Nov; 54(22):7815-33. PubMed ID: 21985639
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3Kα/mTOR inhibitors.
Al-Ashmawy AAK; Ragab FA; Elokely KM; Anwar MM; Perez-Leal O; Rico MC; Gordon J; Bichenkov E; Mateo G; Kassem EMM; Hegazy GH; Abou-Gharbia M; Childers W
Bioorg Med Chem Lett; 2017 Jul; 27(14):3117-3122. PubMed ID: 28571824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
